Literature DB >> 33578969

Histone Acetylation Domains Are Differentially Induced during Development of Heart Failure in Dahl Salt-Sensitive Rats.

Masafumi Funamoto1,2, Yoichi Sunagawa1,2,3, Yasufumi Katanasaka1,2,3, Kana Shimizu1,2, Yusuke Miyazaki1,2,3, Nurmila Sari1, Satoshi Shimizu1,2, Kiyoshi Mori3, Hiromichi Wada2, Koji Hasegawa1,2, Tatsuya Morimoto1,2,3.   

Abstract

Histone acetylation by epigenetic regulators has been shown to activate the transcription of hypertrophic response genes, which subsequently leads to the development and progression of heart failure. However, nothing is known about the acetylation of the histone tail and globular domains in left ventricular hypertrophy or in heart failure. The acetylation of H3K9 on the promoter of the hypertrophic response gene was significantly increased in the left ventricular hypertrophy stage, whereas the acetylation of H3K122 did not increase in the left ventricular hypertrophy stage but did significantly increase in the heart failure stage. Interestingly, the interaction between the chromatin remodeling factor BRG1 and p300 was significantly increased in the heart failure stage, but not in the left ventricular hypertrophy stage. This study demonstrates that stage-specific acetylation of the histone tail and globular domains occurs during the development and progression of heart failure, providing novel insights into the epigenetic regulatory mechanism governing transcriptional activity in these processes.

Entities:  

Keywords:  BRG1; H3K122; H3K9; acetylation; cardiac hypertrophy; heart failure; histone; p300

Mesh:

Substances:

Year:  2021        PMID: 33578969      PMCID: PMC7916721          DOI: 10.3390/ijms22041771

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  65 in total

Review 1.  Epigenetic regulation of pluripotency and differentiation.

Authors:  Michael J Boland; Kristopher L Nazor; Jeanne F Loring
Journal:  Circ Res       Date:  2014-07-07       Impact factor: 17.367

Review 2.  Epigenetic modifications: basic mechanisms and role in cardiovascular disease.

Authors:  Diane E Handy; Rita Castro; Joseph Loscalzo
Journal:  Circulation       Date:  2011-05-17       Impact factor: 29.690

Review 3.  Epigenetic regulation of the cardiovascular system: introduction to a review series.

Authors:  Benoit G Bruneau
Journal:  Circ Res       Date:  2010-08-06       Impact factor: 17.367

Review 4.  Chromatin remodelling during development.

Authors:  Lena Ho; Gerald R Crabtree
Journal:  Nature       Date:  2010-01-28       Impact factor: 49.962

5.  Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300.

Authors:  Jian Qin Wei; Lina A Shehadeh; James M Mitrani; Monica Pessanha; Tatiana I Slepak; Keith A Webster; Nanette H Bishopric
Journal:  Circulation       Date:  2008-08-12       Impact factor: 29.690

Review 6.  Modification of enhancer chromatin: what, how, and why?

Authors:  Eliezer Calo; Joanna Wysocka
Journal:  Mol Cell       Date:  2013-03-07       Impact factor: 17.970

7.  Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo.

Authors:  Shoichi Miyamoto; Teruhisa Kawamura; Tatsuya Morimoto; Koh Ono; Hiromichi Wada; Yosuke Kawase; Akira Matsumori; Ryosuke Nishio; Toru Kita; Koji Hasegawa
Journal:  Circulation       Date:  2006-02-07       Impact factor: 29.690

Review 8.  Lysine acetylation: codified crosstalk with other posttranslational modifications.

Authors:  Xiang-Jiao Yang; Edward Seto
Journal:  Mol Cell       Date:  2008-08-22       Impact factor: 17.970

9.  p300 plays a critical role in maintaining cardiac mitochondrial function and cell survival in postnatal hearts.

Authors:  Yasuaki Nakagawa; Koichiro Kuwahara; Genzo Takemura; Masaharu Akao; Masashi Kato; Yuji Arai; Makoto Takano; Masaki Harada; Masao Murakami; Michio Nakanishi; Satoru Usami; Shinji Yasuno; Hideyuki Kinoshita; Masataka Fujiwara; Kenji Ueshima; Kazuwa Nakao
Journal:  Circ Res       Date:  2009-09-03       Impact factor: 17.367

10.  The primary microRNA-208b interacts with Polycomb-group protein, Ezh2, to regulate gene expression in the heart.

Authors:  Prabhu Mathiyalagan; Jun Okabe; Lisa Chang; Yidan Su; Xiao-Jun Du; Assam El-Osta
Journal:  Nucleic Acids Res       Date:  2013-10-16       Impact factor: 16.971

View more
  6 in total

Review 1.  Acetyltransferase p300 Is a Putative Epidrug Target for Amelioration of Cellular Aging-Related Cardiovascular Disease.

Authors:  Asish K Ghosh
Journal:  Cells       Date:  2021-10-22       Impact factor: 6.600

2.  Chrysanthemum morifolium Extract Ameliorates Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis.

Authors:  Masaya Ono; Yoichi Sunagawa; Saho Mochizuki; Takahiro Katagiri; Hidemichi Takai; Sonoka Iwashimizu; Kyoko Inai; Masafumi Funamoto; Kana Shimizu; Satoshi Shimizu; Yasufumi Katanasaka; Maki Komiyama; Philip Hawke; Hideo Hara; Yoshiki Arakawa; Kiyoshi Mori; Akira Asai; Koji Hasegawa; Tatsuya Morimoto
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

3.  Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1 Complex.

Authors:  Masafumi Funamoto; Yoichi Sunagawa; Mai Gempei; Kana Shimizu; Yasufumi Katanasaka; Satoshi Shimizu; Toshihide Hamabe-Horiike; Giovanni Appendino; Alberto Minassi; Andreas Koeberle; Maki Komiyama; Kiyoshi Mori; Koji Hasegawa; Tatsuya Morimoto
Journal:  Pharmaceutics       Date:  2022-06-15       Impact factor: 6.525

Review 4.  Targeting Epigenetic Regulation of Cardiomyocytes through Development for Therapeutic Cardiac Regeneration after Heart Failure.

Authors:  Lindsay Kraus
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

5.  Effects of high-absorption curcumin for the prevention of hypertensive heart disease: a double-blind, placebo-controlled, randomized clinical study.

Authors:  Masafumi Funamoto; Yoichi Sunagawa; Yasufumi Katanasaka; Toru Kato; Junichi Funada; Yoichi Ajiro; Maki Komiyama; Masaharu Akao; Akihiro Yasoda; Hajime Yamakage; Noriko Satoh-Asahara; Hiromichi Wada; Yasumasa Ikeda; Tatsuya Morimoto; Koji Hasegawa
Journal:  Eur Heart J Open       Date:  2022-09-10

6.  The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2-GATA4 Signaling Pathway.

Authors:  Kana Shimizu; Yoichi Sunagawa; Masafumi Funamoto; Hiroki Honda; Yasufumi Katanasaka; Noriyuki Murai; Yuto Kawase; Yuta Hirako; Takahiro Katagiri; Harumi Yabe; Satoshi Shimizu; Nurmila Sari; Hiromichi Wada; Koji Hasegawa; Tatsuya Morimoto
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.